E3 ligases conjugate ubiquitin (Ub) to specific target proteins, signaling various consequences such as degradation in the proteasome. Deubiquitylases (DUBs) cleave Ub from target proteins. Ub conjugation and deconjugation both have physiological consequences, and both can be manipulated by small molecules for therapeutic effect.
Progenra created the UbiPro™ Drug Discovery Platform — a comprehensive toolbox of HTS assays and technologies to study DUBs and E3 Ligases and perform HTS of our diverse collection of >700,000 drug-like small molecules. Using the UbiPro platform we have discovered and developed diverse set of E3 ligands suitable for PROTACs.